Xspray Pharma Logo

Xspray Pharma

ISIN: SE0009973563 | Ticker: XSPRAY | LEI: 549300NGRQCNZ3X4L157
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Sweden

About Xspray Pharma

Company Description

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development, the first XS004 dasatinib recently filed with the FDA. Xspray’s strategy is to improve the quality of life for cancer patients by launching improved PKI products with relevant medical benefits and cost effectiveness.

Xspray Pharma uses its innovative, patented RightSize™ technology to develop 505(b)(2) improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs), for the treatment of cancer. The segment is the second largest in oncology and where drug prices are very high.

Xspray Pharma applies a unique platform technology:

- Improves the solubility of the active ingredient
- Best-in-class for high dose strength for poorly soluble drugs
- Fully amorphous (non-infringing to many crystalline products patents)

Year founded

2003

Served area

Worldwide

Headquarters

Råsundavägen 12, 16967 Solna – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 605,303,000.00 622,903,000.00 585,430,000.00
Noncurrent Assets N/A 274,288,000.00 340,838,000.00 453,200,000.00
Property Plant And Equipment N/A 42,669,000.00 44,601,000.00 64,603,000.00
Intangible Assets Under Development N/A 231,618,000.00 296,236,000.00 385,597,000.00
Other Noncurrent Receivables N/A N/A 0.00 2,999,000.00
Noncurrent Investments Other Than Investments Accounted For Using Equity Method N/A 1,000.00 1,000.00 1,000.00
Current Assets N/A 331,015,000.00 282,065,000.00 132,229,000.00
Inventories N/A 0.00 6,199,000.00 8,552,000.00
Trade And Other Current Receivables N/A 2,667,000.00 2,473,000.00 2,362,000.00
Cash and cash equivalents 209,872,000.00 325,598,000.00 271,881,000.00 120,166,000.00
Equity And Liabilities N/A 605,303,000.00 622,903,000.00 585,430,000.00
Equity 373,715,000.00 582,587,000.00 591,752,000.00 556,019,000.00
Issued Capital N/A 18,893,000.00 20,680,000.00 22,680,000.00
Retained Earnings N/A -146,689,000.00 -243,387,000.00 -375,057,000.00
Other Reserves N/A 976,000.00 976,000.00 976,000.00
Additional Paidin Capital N/A 709,407,000.00 813,483,000.00 907,420,000.00
Equity Attributable To Owners Of Parent N/A 582,587,000.00 591,752,000.00 556,019,000.00
Noncurrent Liabilities N/A 2,898,000.00 1,185,000.00 560,000.00
Current Liabilities N/A 19,818,000.00 29,966,000.00 28,851,000.00
Trade And Other Current Payables To Trade Suppliers N/A 8,438,000.00 16,865,000.00 14,786,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A 10,401,000.00 11,456,000.00
Other Current Payables N/A 768,000.00 653,000.00 1,043,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 0.00 0.00 0.00
Other Income 1,364,000.00 656,000.00 2,180,000.00
Profit Loss From Operating Activities -53,457,000.00 -97,953,000.00 -133,073,000.00
Finance Income 1,053,000.00 1,259,000.00 1,415,000.00
Finance Costs 6,000.00 4,000.00 12,000.00
Profit Loss Before Tax -52,410,000.00 -96,698,000.00 -131,670,000.00
Income Tax Expense Continuing Operations 0.00 0.00 0.00
Profit (loss) -52,410,000.00 -96,698,000.00 -131,670,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -52,410,000.00 -96,698,000.00 -131,670,000.00
Adjustments For Depreciation And Amortisation Expense N/A 7,689,000.00 8,870,000.00 9,533,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets N/A -113,000.00 98,000.00 0.00
Interest Paid Classified As Operating Activities N/A 8,000.00 4,000.00 147,000.00
Interest Received Classified As Operating Activities N/A 674,000.00 1,878,000.00 1,611,000.00
Cash Flows From Used In Operating Activities N/A -47,792,000.00 -51,607,000.00 -110,179,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 383,000.00 0.00 N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 4,572,000.00 1,313,000.00 24,466,000.00
Cash Flows From Used In Investing Activities N/A -96,828,000.00 -105,818,000.00 -135,345,000.00
Proceeds From Issuing Shares N/A 249,320,000.00 99,877,000.00 100,000,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 936,000.00 2,154,000.00 2,128,000.00
Cash Flows From Used In Financing Activities N/A 260,345,000.00 103,708,000.00 93,809,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 115,726,000.00 -53,717,000.00 -151,715,000.00
Cash and cash equivalents 209,872,000.00 325,598,000.00 271,881,000.00 120,166,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
SWE
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
16.05.24 Anders Bladh Other Buy SEK 503,500.00
02.05.24 Maris Hartmanis Other Other SEK 95,400.00
02.05.24 Christine Lind Other Other SEK 26,640.00
02.05.24 Anders Ekblom Other Other SEK 20,000.00
05.03.24 Robert Molander Other Buy USD 20,000.00
17.01.24 Anders Bladh Other Buy SEK 980,770.12
16.01.24 Anders Bladh Other Buy SEK 1,126,828.68
30.11.23 Anders Bladh Other Other SEK 12,000,000.00
30.11.23 Anders Bladh Other Other EUR 965,800.00
30.11.23 Anders Bladh Other Other SEK 65,120.00

Capital markets information

ISIN

SE0009973563

LEI

549300NGRQCNZ3X4L157

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.